Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1983 Oct;16(4):371-6.
doi: 10.1111/j.1365-2125.1983.tb02180.x.

Pharmacokinetic and pharmacodynamic characteristics of trazodone in the elderly

Comparative Study

Pharmacokinetic and pharmacodynamic characteristics of trazodone in the elderly

A J Bayer et al. Br J Clin Pharmacol. 1983 Oct.

Abstract

The pharmacokinetic and some pharmacodynamic characteristics of a single oral dose of 100 mg trazodone were compared in young and elderly volunteers. The maximum plasma concentration of trazodone was similar in both age groups. The time to maximum concentration was apparently prolonged in four subjects who swallowed the capsule with a minimal volume of fluid. This may have been due to the capsule being retained in the oesophagus. The terminal phase half-life of trazodone was significantly prolonged (P less than 0.05) and area under the plasma concentration-time curve was significantly larger (P less than 0.01) in the elderly. Apparent oral clearance was significantly reduced (P less than 0.01) in the elderly. Measurement of critical flicker fusion threshold and subjective assessment of alertness using a visual analogue scale, confirmed the sedative effect of trazodone in both age groups. The elderly subjects were less alert for a longer period following drug administration than the young. The differing pharmacokinetic and pharmacodynamic characteristics of trazodone in the young and elderly may be due to an age-related reduction in hepatic drug-metabolising activity, a difference in regional distribution or a change in CNS sensitivity to the drug.

PubMed Disclaimer

References

    1. Jpn J Pharmacol. 1968 Dec;18(4):389-96 - PubMed
    1. Metabolism. 1970 Sep;19(9):653-63 - PubMed
    1. Boll Chim Farm. 1970 Jun;109(6):369-73 - PubMed
    1. Gerontologia. 1970;16(6):368-80 - PubMed
    1. Br Med J. 1971 Sep 11;3(5775):607-9 - PubMed

Publication types

LinkOut - more resources